In the phase 3 CERVINO trial, etentamig showed an early overall survival signal in patients with triple-class exposed relapsed/refractory multiple myeloma.
|Articles|November 30, 2018
Meet & Greet the ONCOLOGY Board Members and Editorial Team at ASH 2018
Advertisement
The ONCOLOGY team invites you to attend a meet and greet event with our team and members of our expert Advisory Board at the 60th American Society of Hematology (ASH) 2018 meeting in San Diego, California. Appetizers and drinks will be served!
Meet the following hematology/oncology experts:
- Julie M. Vose, MD, MBA, FACP, FASCO
- John Sweetenham, MD, FRCP
- Stephen T. Rosen, MD
Event Details
Date: Saturday, December 1, 2018
Time: 2:00 PM to 3:00 PM
Location: Booth #3011 in the San Diego Convention Center Exhibit Hall
Advertisement
Related to this article
In the phase 2 IBEX trial, iberdomide plus subcutaneous daratumumab post-transplant maintenance improved MRD status in patients with multiple myeloma.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.
Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 PAPILLON trial.
Longer follow-up is needed for the phase 3 MIDAS trial to determine the impact of MRD conversion on progression-free survival and overall survival.
In the phase 1b CAMMA 1 trial, cevostamab plus pomalidomide and dexamethasone produced overall response rates of 86.2% to 88.0%.
In the phase 1b portion of the MELT-MM trial, elranatamab plus mezigdomide produced a 100% overall response rate in relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
2
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
3
Acting on a HER2 Result and Navigating Access to Therapy
4
FDA Clears TriNav Advance for Expanded Liver Embolization Access
5